Life Sciences CEOs Bracing For Artificial Intelligence

Two-thirds of U.S. executives at the largest pharma and medical device makers were also concerned about integrating this emerging technology into business processes. The biggest barriers to implementing new technologies were the lack of internal skills/knowledge (35 percent) and the complexity of implementations (16 percent), followed by the lack of budget (14 percent), according to the 43 CEOS of the largest U.S. life sciences executives who were surveyed.

"Technology, especially artificial intelligence, will reshape the life sciences industry by shortening drug development times and increasing efficiency," said Alison Little, KPMG Advisory Leader for life sciences. "AI can be applied to finding the best population that would respond to a particular treatment under development, leading to more targeted therapies with better outcomes. AI also has value in transforming core business processes. Many routine tasks tied to finance, administration and compliance can be performed much more efficiently through the use of this technology. CEOs are eager to reap the benefits of AI, but may need to overcome organizational and cultural barriers on the road to implementation."

When it comes to spending on "cognitive technologies" for the next three years, however, a slight majority saw no new investment except for maintaining current business needs. A third (33 percent) saw significant investments and 14 percent saw gradual increases in investments.

Struggling with Revenue Growth

Delivering double digit growth for large drug makers is rare. KPMG's survey found that 93 percent of life sciences CEOs expect annual revenue growth of less than 5 percent and only 7 percent project growth greater than that figure for the next three years. When life sciences CEOs were asked the same question in 2016, 85 percent saw growth below the 5 percent mark.

CEOs tend to be a fairly confident group, but life sciences CEOs based in the United States were less bullish than their peers abroad as 70 percent had a confident outlook about their company's growth prospects and 30 percent had a neutral outlook. In the Asia-Pacific region, 89 percent of life sciences CEOs were confident about their company's growth prospects, while 91 percent in Europe expressed the same sentiment. Only 9 percent had a neutral outlook in Europe and the Asia-Pacific regions.

"Revenue growth is difficult to achieve in the life sciences industry, as patent expirations across a broad range of therapeutic categories act as a major constraint," Little said. "The emergence of biosimilars, coupled with public scrutiny of drug pricing, are creating additional headwinds for the industry. This comes as more payers are demanding that drug and medical device makers show evidence that their treatments provide value and decrease future hospitalizations."

Some of the survey's findings echo KPMG's report from February, Pharma Outlook 2030: From evolution to revolution, which detailed how current business models in the pharmaceutical industry are not reflecting the turbulence in the marketplace and how revenue will fall "well short of forecasts." The report also highlights how companies serving as massive storage houses of data could reshape business models in the pharma industry.

About KPMG LLP

KPMG LLP, the audit, tax and advisory firm (www.kpmg.com/us), is the independent U.S. member firm of KPMG International Cooperative ("KPMG International"). KPMG International's independent member firms have 189,000 professionals, including more than 9,000 partners, in 152 countries. 

SOURCE KPMG LLP

Related Links

http://www.kpmg.com/us